Scientific evidence supports psychedelic therapies for mental health; EU initiative seeks regulated access.
đź”— Read the article on hvg.hu
[This is an automatically generated summary, for reference only]
Scientific research increasingly supports the medical benefits of psychedelics like psilocybin, moving away from outdated views that they cause madness. Progressive psychologists and psychiatrists generally agree on their therapeutic potential for mental health conditions. The European Medicines Agency is funding studies into psilocybin’s role in palliative care for terminally ill patients. While MDMA and ketamine are also showing promise in treating PTSD and depression, respectively, the societal and economic burden of mental illness in Europe is significant, estimated at 4.2% of the EU’s annual GDP. A European Citizens’ Initiative (PsychedeliCare) calls on the European Commission to facilitate timely, affordable, safe, and legal access to innovative psychedelic-assisted therapies, rather than demanding outright legalization. The initiative argues that current psychiatric treatments are often ineffective and points to countries like Australia, Canada, Switzerland, and the US where these therapies are being used. While some EU nations show varied approaches—with Denmark permitting certain treatments and Spain legally allowing ketamine for clinical use—the PsychedeliCare campaign seeks regulatory change through the Commission rather than outright legalization.
